Advanced Accelerator Applications SA products

Our brand name for lutetium Lu 177 vipivotide tetraxetan.

LOCAMETZ, after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy, with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. for selection of patients with metastatic prostate cancer, for whom, lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.

LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

NETSPOT, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. 

This medicinal product is for diagnostic use only. After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for positron emission tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) for localising primary tumours and their metastases.

LysaKare® 25g/25g solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy with Lutathera®.

AAA brand names for FDG (most widely used PET tracer): Oncology, cardiology, neurology. Infectious and inflammatory diseases.

AAA brand names for [18F]-choline (FCH). Oncology.

AAA brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog. Neurology, Oncology.

cGMP produced Lutetium-177, a radiopharmaceutical precursor.